Ira Duarte, Executive Vice President and Chief Financial Officer of Heron Therapeutics, Inc. /DE/ (NASDAQ:HRTX), filed a Form 4 on November 3, 2026, reporting the vesting of restricted stock units and related share disposals on October 30 and October 31, 2026.

Key Highlights

  • RSU vesting on October 30: 13,535 restricted stock units converted to common stock (transaction code M), bringing directly held shares to 298,206.
  • Tax withholding on October 30: 3,850 shares disposed of (transaction code F) at $0.28 per share, reducing the direct holding to 294,356 shares.
  • RSU vesting on October 31: 11,695 restricted stock units converted to common stock (transaction code M), raising the direct holding to 306,051 shares.
  • Tax withholding on October 31: 3,327 shares disposed of (transaction code F) at $0.28 per share, resulting in a post-transaction direct holding of 302,724 shares.
  • Remaining RSU balance: After the two vesting events, Duarte held 175,957 RSUs from the January 30, 2026 grant and 105,249 RSUs from the January 31, 2025 grant, according to the filing.
  • Grant details: The January 30, 2026 grant totaled 216,562 RSUs vesting in 16 equal quarterly installments beginning one quarter after the date of grant.

Duarte's RSU Activity at Heron Therapeutics in Late October 2026

According to the filing, Ira Duarte, serving as EVP and Chief Financial Officer of Heron Therapeutics, Inc. /DE/, reported two separate restricted stock unit vesting events on consecutive days. On October 30, 2026, 13,535 RSUs vested under a grant made on January 30, 2026. The filing notes that this grant originally totaled 216,562 RSUs, scheduled to vest in 16 equal quarterly installments beginning one quarter after the grant date. On the same day, 3,850 shares were disposed of at $0.28 per share under transaction code F, which typically reflects shares withheld for tax purposes.

The following day, October 31, 2026, an additional 11,695 RSUs vested under a separate grant with a date of grant of January 31, 2025, also structured to vest in 16 equal installments beginning one quarter after the grant date, according to the filing. Following this vesting, 3,327 shares were disposed of at $0.28 per share, again under transaction code F. After both days of activity, the filing reports Duarte's direct beneficial ownership of common stock stood at 302,724 shares.

The Form 4 also discloses that following these transactions, Duarte held 175,957 RSUs tied to the January 30, 2026 grant and 105,249 RSUs tied to the January 31, 2025 grant. The filing was signed by Kathryn Lester as attorney-in-fact for Ira Duarte and submitted on November 3, 2026.

What Was Disclosed

The Form 4 filed November 3, 2026 discloses RSU vestings and related share disposals by Heron Therapeutics CFO Ira Duarte on October 30 and October 31, 2026, along with post-transaction beneficial ownership figures for both common stock and remaining RSUs.